Ajinomoto Co., Ltd.

Other

Fujitsu Corporation

Morinaga Milk Industry Co., Ltd.

Kazuo Sugamura

Manabu Suzuki

Junji Hamuro

Yasuhiro Tanaka

Masahiro Murata

Akira Okano

Noriyuki Sato

Kazuo Ohishi

Yoshihiro Morinaga

Yukio Nihei

Nobuyasu Suzuki

Toshihiko Yoshimura

Eiji Nakanishi

Hiroyuki Izawa

Toshiro Shimamura

Yuko Satake

Toshihiro Suzuki

Hideki Matsumoto

Tadakiyo Nakagawa

Shingo Makino

Tatsuhiro Yamada

Hiroeki Sahara

Seiji Toda

Toshihiko Torigoe

Takatoshi Fukuda

Kazuo Tanaka

Yoshiyuki Takahara

Masanori Hattori

Masanobu Yatagai

Akira Chiba

Kazuyoshi Sotoyama

Shingo Hara

Nobuyuki Nemoto

Taro Asao

Tomoko Takeda

Tetsuo Yano

Yuzo Asano

Yasuyo Suga

Chieko Ejima

Kokichi Kikuchi

Toshikazu Takeshita

Mitsuhiko Kojima

Masataka Nakamura

Hironobu Asao

Miwa Taniguchi

Kohichi Fujita

Kunihiko Hagiwara

Yuka Ikenoue

Yoshimasa Wada

Takahiro Yasojima

Hiromitsu Sahara

Tomoyuki Tagami

Manabu Sasaki

Yusuke Miyazaki

Shoji Wakao

Kazunori Horachi

Michio Hibi

Masaki Hashimoto

Miho Ono

Ariko Kodaira

Yoshitomo Chujo

Hiroyuki Matsumoto

Tomohisa Okutsu

Shunsuke Fukuda

Hideki Suzuki

Yoshitomo Chujoh

Syunsuke Fukuda

Hiroshi Arase

Yukihiro Okada

Hiroshi Miyaoku

Keiko Horiuchi

Haruya Sato

Eiko Hayashi

Tomoyuki Tabata

The present disclosure provides a method for manufacturing an excellent denatured whey protein having no adverse effect on the characteristics of a product. A method for manufacturing a denatured whey protein comprising processing a whey protein solution by repeating the following steps (1) and (2) 2 times or more continuously: (1) a step for treating the whey protein solution on pressure at 50 MPa or higher and on heating at 85 to 100&#xb0; C.; and, (2) a step for decompressing to 0.05 to 0.5 MPa after the treating of the aforementioned step (1) and maintaining the temperature within the range of the heating temperature of the aforementioned step (1) &#xb1;10&#xb0; C.

Method for manufacturing denatured whey protein

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-&#x3b1;. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-&#x3b1; production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Therapeutic agent for inflammatory bowel disease and TNF-&#x3b1; production inhibitor

The present invention provides compositions having, as active ingredients, a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Anti-tumor composition

A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&#x3b1; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&#x3b1;.

Heterocyclic compounds

The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Gain setting of a receiving amplifier, is performed by detecting the necessity of gain setting when a receiving amplifier is turned on, requesting WDM transmission equipment in a preceding station to output ASE light; in a WDM transmission equipment of the preceding station, shutting off both passing-through light and added light, and outputting the ASE light corresponding to a predetermined number of wavelengths of signal light; in the receiving amplifier of the WDM transmission equipment in the station of interest, performing the gain setting by use of the ASE light; and on completion of the gain setting, the WDM transmission equipment of the station of interest, requesting the WDM transmission eouipment of the preceding station to halt the ASE light output, and the WDM transmission equipment of the preceding station, halting the ASE light output upon receiving the request and switching the output to an optical signal output.

Gain setting method in wavelength division multiplex transmission equipment

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Yand Yare nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

When a user indicates a point on a display screen of a computer using a pen sensor, first the display screen is divided into a plurality of areas and the areas are displayed by mutually different colors or brightnesses. The plurality of colors or brightnesses displayed are scanned by the pen sensor and the colors or brightnesses detected by the light receiver to judge in which area the indicated point is located. Next, the judged area is further divided into a plurality of areas which are displayed by mutually different colors or brightnesses. Next, a routine similar to the above is successively repeated to narrow down the area in which the point indicated by the pen sensor is located and finally determine the position of the point, that is, the XY coordinates on the display screen.

Pen sensor coordinate narrowing method and apparatus

Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin.

Phenylalanine derivatives

The present invention provides acidic drinks that contain a tofu puree and have improved texture and flavor, namely acidic drinks that compound, as a raw material, a tofu puree having the following physicochemical properties: a) having a viscosity of 20 to 3,000 mPa&#xb7;s, b) having a dynamic storage modulus of 0.2 to 600 Pa, c) having a dynamic loss modulus of 0.2 to 250 Pa, and d) containing particles having an average particle diameter of 2 to 15 &#x3bc;m, and a 90% particle diameter of 35 &#x3bc;m or less. According to the present invention, it is possible to manufacture and provide acidic drinks of a novel type having an excellent texture and a favorable flavor, which cannot be expected with conventional products, and being free from the separation of the components during storage.

Acidic drinks containing tofu puree

In each node of an optical transmission system: an optical preamplifier has an ALC function for maintaining an optical output level constant and an AGC function for maintaining the gain constant; the operational mode of the optical preamplifier is changed from an ALC mode to an AGC mode after the gain is set in the ALC mode; an optical postamplifier has an AGC function; an optical switch unit performs an optical crossconnect operation; and a thru-light-shutoff control unit makes a switch setting so as to shut off pass-through light in the optical switch unit and stop transmission of an optical signal having an unstable level to a next stage when the optical preamplifier operates in the ALC mode, and clears the switch setting when the operational mode of the optical preamplifier is changed to the AGC mode.

Optical transmission system

A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.

Human gastric cancer antigen gene and gastric cancer antigen protein

The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1; 4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1; 4 integrin.

A storing part stores image data of an input image signal; and a control part detects a resolution of the image data from a synchronization signal which is in synchronization with the input image signal, and, controls timing of reading the image data from the storing part according to the thus-detected resolution. The control part detects periods of a horizontal synchronization signal and vertical synchronization signal which are in synchronization with the input image signal, determines a magnification for an image to be output, from a horizontal synchronization interval and a vertical synchronization interval of the image to be output, and the periods of the horizontal synchronization signal and vertical synchronization signal which are in synchronization with the input image signal; and controls the timing of reading the image data from said storing part according to the thus-determined magnification.

Image processing device and image processing method

Growing community of inventors

Kawasaki, Japan

Manabu Suzuki